Pages that link to "Q46325595"
Jump to navigation
Jump to search
The following pages link to Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab (Q46325595):
Displaying 50 items.
- Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker (Q24595773) (← links)
- Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging (Q26783895) (← links)
- Optimal combination of antiangiogenic therapy for hepatocellular carcinoma (Q26799458) (← links)
- The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review (Q26824086) (← links)
- Targeting angiogenesis in gynecologic cancers (Q26824766) (← links)
- Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage? (Q27002538) (← links)
- Hypertension in patients with cancer (Q27003980) (← links)
- The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors (Q27011540) (← links)
- KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials (Q27852414) (← links)
- Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs (Q28070311) (← links)
- Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs (Q28087776) (← links)
- Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature (Q30711589) (← links)
- Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature (Q30942279) (← links)
- Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study (Q33397464) (← links)
- Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial (Q33424566) (← links)
- Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor (Q33684042) (← links)
- Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. (Q33710753) (← links)
- Risks and benefits with bevacizumab: evidence and clinical implications (Q33949406) (← links)
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib (Q34036032) (← links)
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080 (Q34063604) (← links)
- Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers (Q34107482) (← links)
- Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis (Q34245458) (← links)
- Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations (Q34347975) (← links)
- Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis (Q34455292) (← links)
- Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study (Q34466353) (← links)
- Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. (Q34499668) (← links)
- Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy (Q34627959) (← links)
- Biomarkers for anti-angiogenic therapy in cancer. (Q34695003) (← links)
- Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal cancer and their median survival time: A cohort study. (Q34716000) (← links)
- A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer (Q34724614) (← links)
- Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors (Q34803030) (← links)
- Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib (Q34916352) (← links)
- Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium (Q35057364) (← links)
- Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study (Q35120723) (← links)
- The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials (Q35173455) (← links)
- Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin (Q35377689) (← links)
- Therapeutic advances in women's cancers (Q35418973) (← links)
- Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib (Q35583678) (← links)
- Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies (Q35584182) (← links)
- An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity (Q35584752) (← links)
- Targeting angiogenesis in esophagogastric adenocarcinoma (Q35584958) (← links)
- Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer (Q35623279) (← links)
- Cancer therapy and cardiovascular risk: focus on bevacizumab (Q35703835) (← links)
- Cardiotoxicity of molecularly targeted agents (Q35878459) (← links)
- Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. (Q35923178) (← links)
- Reappraising antiangiogenic therapy for breast cancer (Q35966766) (← links)
- Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans (Q36100725) (← links)
- Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer. (Q36194450) (← links)
- Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice (Q36219923) (← links)
- Antiangiogenic therapies in early-stage breast cancer (Q36318210) (← links)